overactive bladder (OAB), symptoms and treatments
by Diane K. Newman, RNC, MSN, CRNP,
FAAN
Overactive bladder (OAB) is increased
urinary urgency, with or without urge urinary
incontinence, usually with frequency and nocturia.
Urgency is the sudden, intense desire to urinate. Urge
incontinence is defined as the unwanted urine leakage (referred to as
"wetting accidents") that happens shortly after urgency. Urge urinary
incontinence is caused by involuntary bladder contractions that occur
as your bladder fills. With urge urinary incontinence, a person
may be aware of the urge sensation but will be unable to stop leakage before
reaching the toilet. Urine loss is usually in large amounts that soak underwear
and even outer clothing. Frequency is urinating more than eight times in a day.
An additional symptom seen very often, especially in the elderly, is
nocturia, awakening more than two times at night to void.
Getting up at night to urinate will often disrupt sleep. Many people find
it difficult to discuss their OAB problem with their doctor or
nurse.
See also: Ask an OAB Nurse, OAB Patient Guide, Treatments
for Overactive Bladder, Controlling
OAB Symptoms
Prevalence of Overactive Bladder (OAB)
Overactive Bladder (OAB) is a bothersome
medical condition that affects more than 17 million men and women of all ages,
although its incidence increases significantly with age. In the past, many
experts believed that such voiding dysfunction symptoms as urgency and frequency
were harmless and did not cause significant problems for individuals.
New research shows that the triad of symptoms - urinary
frequency, urgency and urge incontinence, alone or in
combination - can have a significant impact on someone's quality of life. Other
medical conditions or diseases such as urinary tract infection or bladder tumors
can cause bladder irritation leading to OAB. Some medical
conditions, especially strokes, impair inhibition of bladder contractions
(detrusor hyperreflexia.)
Considered abnormal at any age, overactive bladder is a
highly prevalent condition that affects both men and women but is more common in
women. Many people never report symptoms of overactive
bladder due to their perceptions that treatment is not available
or effective or that the symptoms are normal consequences of aging or
childbirth. Effective treatment includes the combination of drug therapy with
behavioral interventions.
Impact of Overactive Bladder (OAB)
Overactive bladder adversely affects a person's daily
routines and quality of life. Approximately two-thirds of men and women report
that their symptoms have an effect on daily living such that they have a poor
quality of sleep, more depression, and an overall lower quality of daily life
than persons who do not experience overactive bladder. In fact,
compared with persons with diabetes mellitus, persons with overactive
bladder experience a lower quality of life. Weekly or more frequent
urge incontinence with associated urgency and nocturia
has been shown to increase the risk of falls in elderly women who are
attempting to urinate during the night. overactive bladder that
includes urge incontinence is also a major contributor to the
decision to admit an older person to a nursing home.
Overactive bladder has been called the closet disorder since
only one-third of regularly incontinent women discuss their problem with a
health care provider and two-thirds of patients first seeking medical advice
have had their symptoms for more than two years. Instead of seeking help, many
people with overactive bladder adjust their habits and
lifestyle to accommodate the management of symptoms and may adopt such coping
mechanisms as restricting fluids and urinating to a timed schedule or at the
first sensation of urgency. Car trips and vacations are limited. Shopping,
visiting public places, entertaining or socializing are curtailed and in some
cases stopped. Finding accessible public toilets, a behavior referred to as
'toilet mapping', becomes a source of major anxiety. Initially, increasing the
frequency of bladder emptying, often referred to a "defensive voiding" may
reduce the number of incontinent episodes.
See also:
References:
Abrams P, Cardozo L, Fall M, et al. The
standardisation of terminology in lower urinary tract function: report from the
standardisation sub-committee of the International Continence Society.
Urology. 2003;61:37-49.
Abrams P., Freeman, R, Anderstrom, C,
Mattiasson, A. Tolterodine, a new antimuscarinic agent: as effective but better
tolerated than oxybutynin in patients with an overactive bladder. British
Journal of Urology. 1998;81:801-810.
Abrams P., Cardozo, L, Fall,
M, Griffiths, D, Rosier, P, Ulmsten, U, et.al. The standardisation of
terminology of lower urinary tract function. Neurourology and
Urodynamics. 2002;21:167-178.
Anderson, K-E. New parmacologic
targets for the treatment of the overactive bladder: an update. Urology.
2004;ppl 3A):32-41.
Anderson, R., Mobley, D., Blank, B., Saltzman, D.,
Susset, J., Brown, J. Once daily controlled versus immediate-release oxybutynin
chloride for urge urinary incontinence. 1999; The Journal of Urology.
161:1809-1812.
Appell, R. Chancellor, M., Zobrist, H. Thomas, H..
Sanders, S.. Pharmacokinetics, metabolism and saliva output during transdermal
and extended-release oral oxybutynin administration in healthy subjects. Mayo
Clinical Proceedings. 2003;78:696-702.
Burnett, A., Davila, G Willy,
Newman, Diane, Hardestry, S. Clinical and Cost-Effective Strategies in the
Management of Urinary Incontinence. Managed Care Consultant. 2002;5-39.
Burgio K., Locher J., Goode P. Combined Behavioral and Drug Therapy for
Urge Incontinence in Older Women. JAGS. 2000; 48: 370-374.
Chancellor M., Freedman, S, Mitcheson, HD, Antoci, J, Primus, G, Wein,
A. Tolterodine, an effective and well tolerated treatment for urge incontinence
and other overactive bladder symptoms. Clinical Drug Investigations.
2000;19:83-91.
Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic
receptor subtypes and management of the overactive bladder. Urology.
2002;60 (Suppl 5A):82-89.
Cruz, F. Mechanisms involved in new therapies
for overactive bladder. Urology. 2004;sppl 3A):65-73.
Davila, G
Willy, Daugherty CA, Sanders SW. A short-term, multicenter, randomized
double-blind dose titration study of the efficacy and anticholinergic side
effects of transdermal compared to immediate release oral oxybutynin treatment
of patients with urge urinary incontinence. The Journal of Urology.
2001;166(1):140-145.
Diokno, A., Appell, R., Sand, P., Dmochowski,
R., Gburek, B., Klimberg, I., Kell, S.. Prospective, randomized, double-blind
study of the efficacy and tolerability of the extended-release formulations of
oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.
Mayo Clinical Proceedings. 2003;78:687-695.
Dmochowski RR, Davila
GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients
with urge and mixed urinary incontinence. J Urology. 2002;168:580-586.
Halaska, M., Ralph, G., Wiedeman, A., Rimus, G., Ballering, B., Hofner,
K & Jona., G. Controlled, double-blind, multicentre clinical trial to
investigate long-term tolerability and efficacy of trospium chloride in patients
with detrusor overactivity. World J Urology. 2003;20:392-399.
Hampel, CC., Wienhold, D., Benken, N., Egersmann, C., Thuroff, JW.
Definition of overactive bladder and epidemiology of urinary incontinence.
Urology. 1997;50[suppl 6A]:4-14.
Hofner, K., Oelke, M., Machtens,
S., Grunewald, V. Trospium chloride-an effective drug in the treatment of
overactive bladder and detrusor hyperreflexia. World J Urology.
2001;19:336-343.
Kelleher, Con. Economic and Social Impact of OAB.
European Urology Supplements. 2002;1:11-16.
Kelleher, C, Pleil,
A.M., Reese, P. R., Burgess S. M,, Brodish, P. H. How much is enough and who
says so? The case of King's Health Questionnaire and overactive bladder.
BJOG. 2004;111:605-612.
Hu TW, Wagner TH, Bentkover JD. Estimated
economic costs of overactive bladder in the United States. Urology.
2003;61:1123-1128.
Madersbacher H, Stohrer M, Richter R, et al. Trospium
chloride versus oxybutynin: a randomized, double-blind, multicenter trial in the
treatment of detrusor hyper-reflexia. Br J Urol. 1995;75:452-456.
Milsom, I, Stewart, W, Thuroff, JW The Prevalence of Overactive Bladder.
The American Journal of Managed Care. 2000; 6(11), Sup:S565-S573.
Murphy M, Carmichael AJ. Transdermal drug delivery systems and skin
sensitivity reactions. Incidence and management. Am J Clin Dermatol.
2000;1:361-368.
Newman, D.K. & Wein, A.J. Overcoming Overactive
Bladder, New Harbinger, Los Angeles, California, 2004.
Newman, Diane.
Managing and Treating Urinary Incontinence. Baltimore: Health Professions
Press;2002.
Ouslander, J.O. Management of overactive bladder.
JAMA 2004;350(8):786-799.
Shah D, Badlani G. Treatment of
overactive bladder and incontinence in the elderly. Rev Urol.
2002;4(Suppl 4):S38-S43.
Stewart W, Herzog R, Wein A. The prevalence and
impact of overactive bladder in the U.S.: results from the NOBLE program. 2001;
Neurourology Urodynamics. 20:406-408.
Wein AJ, Rovner ES.
Definition and epidemiology of overactive bladder. Urology. 2002;60(Suppl
5A):7-12.
Wein AJ, Rovner ES. The overactive bladder: an overview for
primary care health providers. 2000; Int J Fertil Womens Med. 1999; 44:
56-66.
Zinner, N., Gittelman, M., Harris, R., Susset, J., Kanellos, A.,
Auerbach, S. Trospium cloride improves overactive bladder symptoms: a
multicenter phase III trial. Journal of Urology. 2004;171:2311-2315.
Posted December 2003
Updated August 2009
 | Incontinence Forums |
Interstim therapy  I have an Interstim system but will probably have to lose it. I am much improved with it but I still have a lot of symptoms. I think people forget just how bad they were without it. I have my favorite settings but after a while I think my body adjusts to ... (read more) |
|
Interstim query  Have any forum members had an interstim unit by Medtronic implanted? What luck, if any, have you had with it? And if successful, how long before you found the right setting for that success? So far, I haven't had the success my urologist anticipated af... (read more) |
|
Tena for Men- shaped pads  I have total bladder incontinence and partial bowel issues and I need something that is not noticeable and that fits me well, and I use the Attends with elastic waistband.
The benefits of disposables is that it is very easy to do a quick change and simpl... (read more) |
|
unexplained urgency  You might want to submit your question to our nurse expert at:
ask an incontinence nurse
A nurse practitioner will respond and may have some suggestions for you. Good luck.... (read more) |
|
Free yourself from diapers  Do you experience urinary incontinence? Then you know that adult diapers are not good choices because they are not easy to conceal and can cause much embarrassment. However, many discreet and comfortable alternatives for men are available.
âfex® is an ... (read more) |
|